Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ProQR Therapeutics N.V. before investing.

In this article, we go over a few key elements for understanding ProQR Therapeutics N.V.’s stock price such as:

• ProQR Therapeutics N.V.’s current stock price and volume
• Why ProQR Therapeutics N.V.’s stock price changed recently
• Upgrades and downgrades for PRQR from analysts
• PRQR’s stock price momentum as measured by its relative strength

About ProQR Therapeutics N.V. (PRQR)

Before we jump into ProQR Therapeutics N.V.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Want to learn more about ProQR Therapeutics N.V.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ProQR Therapeutics N.V..

ProQR Therapeutics N.V.’s Stock Price as of Market Close

As of January 16, 2026, 4:00 PM, CST, ProQR Therapeutics N.V.’s stock price was $1.650.

ProQR Therapeutics N.V. is up 4.43% from its previous closing price of $1.580.

During the last market session, ProQR Therapeutics N.V.’s stock traded between $1.600 and $1.740. Currently, there are approximately 123.60 million shares outstanding for ProQR Therapeutics N.V..

ProQR Therapeutics N.V.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ProQR Therapeutics N.V. Stock Price History

ProQR Therapeutics N.V.’s (PRQR) price is currently down 18.32% so far this month.

During the month of January, ProQR Therapeutics N.V.’s stock price has reached a high of $2.280 and a low of $1.580.

Over the last year, ProQR Therapeutics N.V. has hit prices as high as $3.100 and as low as $1.070. Year to date, ProQR Therapeutics N.V.’s stock is down 18.32%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ProQR Therapeutics N.V. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 16, 2026, there were 0 analysts who downgraded ProQR Therapeutics N.V.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate ProQR Therapeutics N.V.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ProQR Therapeutics N.V.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

ProQR Therapeutics N.V.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ProQR Therapeutics N.V. (PRQR) by visiting AAII Stock Evaluator.

Relative Price Strength of ProQR Therapeutics N.V.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 16, 2026, ProQR Therapeutics N.V. has a weighted four-quarter relative price strength of -9.19%, which translates to a Momentum Score of 23 and is considered to be Weak.

Want to learn more about how ProQR Therapeutics N.V. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ProQR Therapeutics N.V. Stock Price: Bottom Line

As of January 16, 2026, ProQR Therapeutics N.V.’s stock price is $1.650, which is up 4.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ProQR Therapeutics N.V. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.